We aimed to compare the efficacy of three tadalafil regimens for patients with type-2 diabetes mellitus (DM), at least one microvascular complication and erectile dysfunction (ED). Sixty patients attending our urology clinic with erectile problems and diagnosed with ED, having DM for at least 5 years, and at least one microvascular complication linked to DM were identified and randomly divided into three groups-Group I: used 5 mg tadalafil daily, Group II: used 20 mg tadalafil 2 h before sexual relations twice a week and Group III: used 5 mg tadalafil daily and an extra 15 mg tadalafil 2 h before sexual relations twice a week. After treatment, the median International Index of erectile function (IIEF-5) scores were significantly higher in Group III (15) compared to Groups I (8.5, p = 0.01) and II (9, p = 0.035). The groups were comparable in terms of the percentage of positive responses to the sexual encounter profile (SEP) 2 and the Global Assessment Questionnaires (GAQ)-1. However, the percentage of patients with positive responses to SEP-3 (20%, 40% and 75%, respectively) (p = 0.002) and GAQ-2 (20%, 45% and 75%, respectively) (p = 0.002) was significantly higher in Group III. Therefore, using a combination treatment (daily 5 mg + 15 mg when needed) to treat erectile function in patients with DM-related ED in the first stage may be more efficient with the same reliability and greater patient satisfaction.
Objective: This study aimed to investigate the relationship between Fetuin-A glycoprotein, a known systemic and localized calcification inhibitor, and urinary system stone disease. Material and Methods: A total of 63 patients with urinary stone disease and 70 healthy controls were included. Serum Fetuin-A levels were measured using enzyme-linked immunosorbent assay, and various biochemical parameters were analyzed. Statistical comparisons were performed by using Pearson correlation to determine relationships, with significance set at p0.05). The mean age was 42.87 ± 11.0 years in the stone group and 41.6 ± 11.7 years in the control group (p=0.497). In the stone group, 65% were male and 35% female, while in the control group, 66% were male and 34% female, with no significant difference in gender distribution (p=0.831). Body mass index (BMI) was 25.3 ± 2.57 kg/m² in the stone group and 26.9 ± 3.08 kg/m² in the control group, also showing no significant difference (p=0.067). No correlations were found between serum Fetuin-A levels and other parameters such as age, BMI, or biochemical markers. Conclusion: Although some previous studies have suggested a relationship between Fetuin-A levels and urinary stone disease, this study found no significant association. Further research focusing on genetic polymorphisms of Fetuin-A may clarify its role in stone formation.